AKRO News and Press, Akero Therapeutics Inc. From 08/12/19

Akero Therapeutics (NASDAQ: AKRO ): Q2 GAAP EPS of -$2.21 misses by $1.76 . Cash and cash equivalents of $162.6M Press Release More news on: Akero Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news,

SAN FRANCISCO , Aug. 12, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today provided a bus...

Akero Therapeutics (NASDAQ: AKRO ) initiated with Buy rating and $28 (41% upside) price target at Jefferies. Shares down a fraction premarket. More news on: Akero Therapeutics, Inc., Atreca, Inc., Personalis, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you ca...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , iTunes...

Akero Therapeutics (NASDAQ: AKRO), a clinical-stage biotechnology company developing transformational treatments for people with non-alcoholic steatohepatitis (“NASH”) and other serious metabolic disorders, has closed its initial public offering, resulting in gross proceeds of ap...

The first patient has been dosed in a Phase 2a clinical trial, BALANCED , evaluating Akero Therapeutics' (NASDAQ: AKRO ) lead candidate AKR-001 for the treatment of nonalcoholic steatohepatitis (NASH). More news on: Akero Therapeutics, Inc., Healthcare stocks news, Read more ...

SAN FRANCISCO , July 2, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced the dosing...